雷珠单抗玻璃体腔注射联合复方丹参静脉滴注治疗视网膜分支静脉阻塞引起的黄斑水肿疗效分析

Ranibizumab combined with Compound Salvia in treating macular edema secondary to branch retinal vein occlusion

目的探讨雷珠单抗玻璃体腔内注射联合复方丹参静脉注射治疗视网膜分支静脉阻塞(BRVO)伴发黄斑水肿的临床疗效。方法回顾性分析2014年1月至2014年5月就诊于我院眼科的视网膜分支静脉阻塞伴发黄斑水肿患者79例(79只眼),分为2组。治疗组45例(45只眼)予雷珠单抗玻璃体腔内注射联合复方丹参静脉滴注,对照组34例(34只眼)为单纯雷珠单抗玻璃体腔内注射治疗。统计分析治疗前及治疗后1周、3个月、6个月患者患眼最佳矫正视力、黄斑中心凹视网膜厚度(CMT)的改变,以及平均球内注射次数。结果治疗后1周治疗组与对照组最佳矫正视力均有提高,2组相比无明显差异(P>0.05),治疗后3个月、6个月治疗组最佳矫正视力提高均高于对照组(P<0.05)。治疗后1周,3个月,6个月治疗组黄斑水肿程度较治疗前有所下降,二者有明显差异(P<0.05);治疗后1周治疗组与对照组黄斑水肿程度均有所下降,2组相比无明显差异(P>0.05),治疗后3个月、6个月治疗组黄斑水肿程度均较对照组有明显下降,二者有明显差异(P<0.05);治疗后1周时,治疗组与对照组治疗疗效比较无明显差异(P>0.05),治疗后3个月、6个月时治疗组疗效明显优于对照组,二者相比有明显差异(P<0.05)。治疗至6个月时,治疗组显效患者与有效患者平均打针次数较对照组均有明显减少,二者比较有明显差异(P<0.05)。结论采用雷珠单抗联合复方丹参治疗视网膜分支静脉阻塞伴发黄斑水肿与单纯雷珠单抗药物治疗比较,可以在更少的球内注射次数的基础上更有效地改善患者视力,减轻黄斑水肿情况,是临床上有效的治疗方式。

OBJECTIVE To study the effect of intravitreal ranibizumab injection combined with intravenous compound salvia injection drip in the treatment of patients with macular edema secondary to branch retinal vein occlusion （BRVO ）. METHODS Seventy-nine patients of branch retinal vein occlusion with macular edema were analyzed retrospectively. Forty-five patients in the treatment group were treated with intravitreal ranibizumab injection combined with intravenous compound salvia injection drip, 34 patients in the control group were treated with ranibizumab injection only. All patients were recorded and analyzed changes of clinical effects after 1 week, 3 months, 6 months of treatment. BCVA and CMT were measured. RESULTS After 1 week of treatment, the two groups＂ BCVA were significantly improved than preoperation （P〈0.05）, and there was no significant difference between the two group （P〉0.05）; after 3 months and 6 months of treatment, the treatment group＇s BCVA improved significantly than control group （P〈0.05）. Both groups showed significant reduce of macular edema than preoperation （P〈0.05）, and there was no significant difference between the two groups （P〉0.05）; after 3 months and 6 months of treatment, the treatment group＇s macular edema reduced much significantly than control group （P〈0.05）.The total effect between the two groups had no difference after 1 week treatment （P〉0.05）, but after 3months and 6 months of treatment, it showed better total effect in the treatment group than the control group （P〈0.05） .After 6 months oftreatment,the numbers oi injections ot cure and effective patients were both less in the treatment group than the control group （P〈0.05）. CONCLUSIONSIntravitreal ranibizumab injection combined with intravenous compound salvia injection drip could effectivelyimprove the therapeutic effect in patients with macular edema secondary to branch retinal vein occlusion, and could effectively improve the visual activity and reduce the macular edema with less number of injections. The treatment showed great potential in the clinical use.